Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNYSE:AGENYSE:ANVSOTCMKTS:LTUSNASDAQ:REPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsAGEAgeX Therapeutics$3.23$11.07▼$35.71$11.99M1.183,849 shs3,700 shsANVSAnnovis Bio$9.88+9.9%$10.36$5.42▼$22.49$108.78M1.59265,663 shs240,766 shsLTUSLotus Pharmaceuticals$0.01$0.01$0.00▼$0.01$18.86M-0.42159 shsN/AREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-88.78%AGEAgeX Therapeutics0.00%0.00%-32.77%+4,313.52%+2,859.51%ANVSAnnovis Bio-9.39%-22.74%-3.41%-21.88%-44.39%LTUSLotus Pharmaceuticals0.00%+40.00%-6.67%+100.00%-36.36%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANVSAnnovis Bio1.5909 of 5 stars3.41.00.00.02.91.70.6LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/AAGEAgeX TherapeuticsN/AN/AN/AN/AANVSAnnovis Bio2.75Moderate Buy$27.75180.87% UpsideLTUSLotus PharmaceuticalsN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest ADMP, REPH, LTUS, AGE, and ANVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00AGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00ANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AREPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AAGEAgeX Therapeutics-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)ANVSAnnovis Bio-$56.20M-$6.22N/AN/AN/AN/A-446.06%-257.97%5/9/2024 (Estimated)LTUSLotus PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AREPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AAGEAgeX TherapeuticsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19AGEAgeX TherapeuticsN/A0.130.36ANVSAnnovis BioN/A2.392.39LTUSLotus PharmaceuticalsN/AN/AN/AREPHRecro Pharma2.273.242.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%AGEAgeX Therapeutics12.50%ANVSAnnovis Bio15.83%LTUSLotus PharmaceuticalsN/AREPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%AGEAgeX Therapeutics6.50%ANVSAnnovis Bio38.30%LTUSLotus PharmaceuticalsN/AREPHRecro Pharma14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableANVSAnnovis Bio511.01 million6.79 millionOptionableLTUSLotus Pharmaceuticals2332.69 billionN/ANot OptionableREPHRecro Pharma18556.42 million48.41 millionOptionableADMP, REPH, LTUS, AGE, and ANVS HeadlinesSourceHeadlineDorf Ketal's Indian unit acquires veterinary pharma brandvccircle.com - April 10 at 10:57 PMFuji Pharma Co. Ltd.wsj.com - January 30 at 3:34 PMAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croremoneycontrol.com - November 22 at 10:47 PMRetaining the human element of AI within pharma and healthcarepharmaphorum.com - November 21 at 10:06 AMHere's what Wall Street expects from Recro Pharma's earnings reportmarkets.businessinsider.com - November 7 at 12:00 PMUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitstheguardian.com - August 16 at 1:59 AMMankind Pharma share pricelivemint.com - August 9 at 12:30 PMWhat Wall Street expects from Recro Pharma's earningsmarkets.businessinsider.com - August 9 at 7:25 AMMankind Pharma Ltd (MNKI)investing.com - August 3 at 9:00 AMEversana and Amazon plan generative AI push in pharmapharmaphorum.com - July 30 at 11:21 PMAurobindo Pharma Ltd.ndtv.com - July 25 at 12:39 AMBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsbizjournals.com - June 30 at 12:44 PMPharma reform: Patients can’t afford to wait. Act now.politico.eu - June 13 at 3:41 PMSun Pharma reports "information security incident"; isolates impacted IT assetshealth.economictimes.indiatimes.com - March 9 at 7:26 AMWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLijr.com - March 2 at 12:30 AMAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendmoneycontrol.com - February 17 at 8:43 PMPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusfinancialexpress.com - December 20 at 8:48 AMPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLbenzinga.com - June 24 at 9:08 AMSocietal CDMO Increuters.com - April 20 at 9:24 AMRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformationfinanznachrichten.de - March 22 at 10:51 PMRecro Pharma Rebrands to Societal CDMO Inc.contractpharma.com - March 22 at 5:51 PMIs Recro Pharma (REPH) a Worthy Investment?finance.yahoo.com - March 22 at 8:32 AMRecap: Recro Pharma Q4 Earningsbenzinga.com - March 1 at 11:55 PMRecro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilitiescontractpharma.com - February 23 at 9:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come2 Data Storage Device Stocks Thriving From the AI BoomApril 2, 2024 7:25 AMView 2 Data Storage Device Stocks Thriving From the AI BoomMicron Technology Results Proves AI is Driving Storage DemandMarch 26, 2024 7:35 AMView Micron Technology Results Proves AI is Driving Storage DemandYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyAll Headlines Company DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.AgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Annovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Lotus PharmaceuticalsOTCMKTS:LTUSLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Recro PharmaNASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.